Aquestive Therapeutics, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Aquestive Therapeutics, Inc. (AQST) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of -$72.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2026-03-04
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-09-30 was -$72.00K.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-06-30 was -$19.00K.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-03-31 was -$702.00K.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2024-09-30 was -$202.00K.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2024 was -$1.35M, a 150.75% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $2.66M.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was -$3.00K.
- Aquestive Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2021 was -$14.00K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2025-09-30 | -$72.00K 10-Q · filed 2025-11-05 | -$91.00K derived: sum of 2 quarters · filed 2025-11-05 | -$793.00K derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2025-06-30 | -$19.00K 10-Q · filed 2025-11-05 | -$721.00K derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2025-03-31 | -$702.00K 10-Q · filed 2025-11-05 | ||||
| 2024-12-31 | -$1.35M 10-K · filed 2026-03-04 | $7.06M 10-K · filed 2025-03-05 | |||
| 2024-09-30 | -$202.00K 10-Q · filed 2025-11-05 | -$207.00K derived: sum of 2 quarters · filed 2025-11-05 | -$1.10M derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$5.00K 10-Q · filed 2025-11-05 | -$898.00K derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-31 | -$893.00K 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $2.66M 10-K · filed 2025-03-05 | -$11.00K 10-K · filed 2024-03-05 | |||
| 2023-06-30 | -$3.00K 10-Q · filed 2024-11-04 | -$11.00K derived: sum of 2 quarters · filed 2024-11-04 | |||
| 2023-03-31 | -$8.00K 10-Q · filed 2024-11-04 | ||||
| 2022-12-31 | -$3.00K 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | -$3.00K 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | -$14.00K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$9.00K 10-Q · filed 2022-11-01 | -$13.00K derived: sum of 2 quarters · filed 2022-11-01 | |||
| 2021-06-30 | -$4.00K 10-Q · filed 2022-11-01 | ||||
| 2020-12-31 | -$99.00K 10-K · filed 2022-03-08 | ||||
| 2020-06-30 | -$52.00K 10-Q · filed 2021-11-02 | -$89.00K derived: sum of 2 quarters · filed 2021-11-02 | |||
| 2020-03-31 | -$37.00K 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |